Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This study aims to explore a new therapeutic approach for advanced soft tissue sarcoma (STS)
by investigating the safety, tolerability, and maximum tolerable dose (MTD) of DPPG2-TSL-DOX
combined with regional hyperthermia (RHT) in patients who have been pre-treated with
doxorubicin (DOX).